Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

Cerus Corporation (CERS) 4.41 -0.15
Price Open:4.54Day's Range:0.00000 - 5.57000
Price Close:4.5552wk Range:0.00000 - 5.57000
Price Day Change:-0.15Volume:526,681
Price % Change:-3.30Market Cap:306.8M
Bid:4.41000PE Ratio:0
Ask:4.59000EPS Diluted:-0.34
Trade CERS NOW!

The Latest On CERS

Cerus Announces FDA Agreement on Modular PMA App Submission Process for INTERCEPT Platelets 4/24/13 8:33am
Cerus Announces Proposed Public Offering of Common Stock 3/13/13 4:04pm
Cerus, FDA Reach Agreement on Modular Premarket Approval Application Submission Process for INTERCEPT Plasma 12/13/12 9:37am
Cerus Announces Deal with Swiss Red Cross for Initial Deployment of INTERCEPT Blood System 12/4/12 9:36am
Benzinga's Top Pre-Market Gainers 10/9/12 8:19am
Benzinga's Top Initiations 10/8/12 7:49am
Cerus Enters Partnership With American Red Cross and Blood Systems 9/11/12 8:51am
Cerus Announces INTERCEPT Blood System for Platelets Regulatory Submission for Approval in South Africa 9/4/12 8:32am
UPDATE: Cantor Fitzgerald Initiates Buy, $5.50 on Cerus Corporation 4/17/12 10:06am
UPDATE: Cantor Fitzgerald Initiates Buy, $5.50 on Cerus Corporation 4/17/12 10:06am
Cerus Announces New Supply Agreement with Largest Blood Service in Saudi Arabia 4/3/12 8:46am
Cerus Submits Investigational Device Exemption Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study 3/21/12 8:32am
more
Press Releases
Cerus Initiates Patient Enrollment in European Phase III Clinical Trials for INTERCEPT Red Blood Cells for Acute and Chronic Anemia 6/11/13 Business Wire
First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus 5/28/13 Business Wire
Cerus Corporation Reports First Quarter 2013 Results 4/30/13 Business Wire
Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets 4/24/13 Business Wire
Cerus to Release First Quarter 2013 Results on April 30, 2013 4/17/13 Business Wire
Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated Platelet Components 4/3/13 Business Wire
Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria 3/15/13 Business Wire
Cerus Prices Public Offering of Common Stock 3/14/13 Business Wire
Cerus Announces Proposed Public Offering of Common Stock 3/13/13 Business Wire
Cerus Corporation Reports Fourth Quarter and Year-End 2012 Results 2/28/13 Business Wire
Cerus to Present at the Cowen and Company 33rd Annual Health Care Conference on March 6, 2013 2/27/13 Business Wire
Cerus to Release Fourth Quarter and Year-End 2012 Results on February 28, 2013 2/14/13 Business Wire

Get the latest CERS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Cerus Corporation stock price.

Partner Headlines
Cerus Corporation (CERS) CEO William Mariner Greenman buys 3,200 Shares 11/20/12
New Analyst Coverage 10/8/12
Cerus Corp. Reports Operating Results (10-Q) 8/8/12
Cerus Corp. Reports Operating Results (10-Q) 5/7/12
Cerus Corp. Reports Operating Results (10-K) 3/5/12
Early Research Calls ( NYX, DPZ, MRO, CRH, PCS, APOL, WNR, WTR, CERS, FARO ) 2/29/12
2 Breakout Biotechs to Watch 12/7/11
Cerus Corp. Reports Operating Results (10-Q) 11/3/11
Company News for March 07, 2011 - Corporate Summary 3/7/11
Jones Soda, Callon Petroleum: Early Volume Plays
5 Bargain Biotech Stocks
Insiders Trading CERS, IL, MDCA, UA